News | March 30, 2010

Investigational Study Examines Portable Artificial Heart Driver System


March 30, 2010 – The FDA granted an investigational device exemption (IDE) for a clinical study of the Freedom portable driver system to power SynCardia's Total Artificial Heart. The study is designed to demonstrate that stable Total Artificial Heart patients in the U.S. can manage their portable driver outside the hospital environment, including at home and in step-down facilities.

While the Total Artificial Heart has the one of the highest bridge to transplant rates of all approved mechanical circulatory support devices, the major drawback is it confines patients to the hospital while they await a transplant. This is because the only FDA-approved driver for powering the device is the 418-pound hospital driver nicknamed “Big Blue.” Patients who meet study criteria will have the option to be discharged from the hospital with the Freedom driver, with the goal of enabling them to resume normal activities. The portable driver weighs 13.5-pounds, which includes two onboard lithium-ion batteries and a power adaptor. It is carried by the patient in a backpack or shoulder bag.

“While waiting for a transplant, patients can stay in the hospital for several months and in some rare cases, more than a year,” said Dr. Stephen Clayson, associate surgical director of the Utah Artificial Heart Program at Intermountain Medical Center. “We are pleased to initiate the IDE clinical study and evaluate the use of the Freedom driver to power the Total Artificial Heart. If the IDE clinical study of the Freedom driver is successful, patients will be able to sleep in their own bed, spend time with their families and be more self-sufficient.”

The study is designed to demonstrate that the driver is a suitable pneumatic driver for stable artificial heart patients and can be used safely at home. The trial is expected to enroll 60 patients and will follow them until transplant, 90 days after discharge or death. Centers anticipated to participate in the study include University Medical Center at the University of Arizona, Intermountain Medical Center and Virginia Commonwealth University Medical Center.

The Freedom driver uses a “dark cockpit” design, meaning the driver only flashes a light and sounds an alarm when something requires the user’s attention. The Freedom driver is serviced by replacement via express delivery. No onsite repair or inventory of parts is required by the hospital.

On March 1 the Freedom driver received CE approval for use in Europe.

For more information: www.syncardia.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now